Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportRadiopharmaceutical Chemistry: New Radiopharmaceuticals-Oncology

F-18 labeled ethanolamine derivatives for tumor imaging - Comparison with F-18 ethylcholine

Sabine Zitzmann-Kolbe, Holger Siebeneicher, Martin Schäfer, Mathias Berndt, Lutz Lehmann, Markus Berger, Volker Gekeler, Ludger Dinkelborg and Michael Eisenhut
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1511;
Sabine Zitzmann-Kolbe
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holger Siebeneicher
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schäfer
1German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Berndt
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutz Lehmann
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Berger
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Volker Gekeler
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludger Dinkelborg
2Bayer Schering Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Eisenhut
1German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1511

Objectives Choline and ethanolamine are essential building blocks for the biosynthesis of cell-membrane phospholipids. Owing to accelerated proliferation, tumor cells have an increased demand for new membrane constituents and thereby rely on the uptake of choline and ethanolamine among other membrane components. [C-11]choline is a widely used PET tracer for prostate cancer imaging including the [F-18]derivatives fluormethyl- and fluoroethylcholine.

Methods It has been shown that the uptake of [C-14]ethanolamine and [C-14]dimethyl-aminoethanol is higher than the uptake of [C-14]choline in various cell lines (Mintz et al. Cancer Biol Ther 2008;7:1). Therefore, we synthesized a series of N-substituted N-([F-18]fluoroethyl)-2-aminoethanol derivatives (substituents H, Me, Et) and investigated them in comparison to [F-18]fluoroethylcholine for their acumulation in tumor cell lines with a focus on prostate tumors.

Results We could show that the respective [F-19]ethanolamine derivatives were able to effectively compete with [H-3]ethanolamine and [H-3]choline for uptake into tumor cells. The uptake and kinetics of the [F-18]ethanolamine derivatives into PC-3, Hep G2, Du-145, HCT-116, A375 and A549 cells proved to be better than the uptake of [F-18]fluoroethylcholine.

Conclusions Among the three aminoalcohol derivatives N-methyl-N-([F-18]fluoroethyl)-2-aminoethanol (FE-AA1) showed the best in vitro and in-vivo results

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
F-18 labeled ethanolamine derivatives for tumor imaging - Comparison with F-18 ethylcholine
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
F-18 labeled ethanolamine derivatives for tumor imaging - Comparison with F-18 ethylcholine
Sabine Zitzmann-Kolbe, Holger Siebeneicher, Martin Schäfer, Mathias Berndt, Lutz Lehmann, Markus Berger, Volker Gekeler, Ludger Dinkelborg, Michael Eisenhut
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1511;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
F-18 labeled ethanolamine derivatives for tumor imaging - Comparison with F-18 ethylcholine
Sabine Zitzmann-Kolbe, Holger Siebeneicher, Martin Schäfer, Mathias Berndt, Lutz Lehmann, Markus Berger, Volker Gekeler, Ludger Dinkelborg, Michael Eisenhut
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1511;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Radiopharmaceutical Chemistry: New Radiopharmaceuticals-Oncology

  • 99mTc-Labeled carbonic anhydrase IX (CA IX) inhibitors for molecular imaging of cancer
  • 99mTc labeled doxorubicin as a potential radioligand for the early cancer detection and treatment response monitoring
  • 188Re-SOCTA-Chitosan and hepatoma animal model study
Show more Radiopharmaceutical Chemistry: New Radiopharmaceuticals-Oncology

New Radiopharmaceuticals-Oncology Posters

  • Automated synthesis of 16β-[18F]fluoro-5α-dihydrotestosterone using a plastic cassette-type FDG synthesizer
  • Radiolabeling of DOTATOC with 44T/44Sc generator-derived 44Sc
  • Preparation and evaluation of a tumor-associated antigen mucin (MUC1) and tumor-associated monoclonal antibody-derived hybrid peptide as a breast cancer imaging agent
Show more New Radiopharmaceuticals-Oncology Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire